Efficacy of glimepiride in type 2 diabetic patients treated with glibenclamide.
Multicentric study was conducted to evaluate the efficacy of glimepiride in the oral hypoglycemic agents therapy of type 2 diabetic patients treated with glibenclamide so far, and to claim an adequate use of this new generation sulfonylurea. In 66 diabetic outpatients, glibenclamide was switched to glimepiride. After 6 months' therapy, a significant reduction in fasting plasma IRI was observed in relatively hyperinsulinemic patients. In addition, weight reduction was achieved in patients with insulin resistance during this study. These findings suggest that glimepiride improves insulin resistance in hyperinsulinemic patients treated with glibenclamide. Also, glimepiride is favored especially for overweight, insulin-resistant patients inadequately controlled by glibenclamide.
Hamaguchi
Tomoya
T
HOSS Conference Group, Hyogo, Japan. tomhamag@hyo-med.ac.jp
Hirose
Takahisa
T
Asakawa
Hideki
H
Itoh
Yoshiharu
Y
Kamado
Keiji
K
Tokunaga
Katsuto
K
Tomita
Koji
K
Masuda
Hiroshi
H
Watanabe
Nobuaki
N
Namba
Mitsuyoshi
M
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; C057619:glimepiride